EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

Jie Zhang, Luming Wu, Tingwei Su, Haoyu Liu, Lei Jiang, Yiran Jiang, Zhiyuan Wu, Lu Chen, Haorong Li, Jie Zheng, Yingkai Sun, Hangya Peng und 4 weitere

Frontiers in Endocrinology · 2024

DOI: 10.3389/fendo.2024.1365321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2024. Verfasst von Jie Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai National Clinical Research Center fo…. Hauptthemen laut MEDLINE: Mitotane, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adrenocortical carcinoma (ACC) is an aggressive endocrine malignancy with limited therapeutic options. Treating advanced ACC with mitotane, the cornerstone therapy, remains challenging, thus underscoring the significance to predict mitotane response prior to treatment and seek other effective therapeutic strategies.

Objective

We aimed to determine the efficacy of mitotane via an in vitro assay using patient-derived ACC cells (PDCs), identify molecular biomarkers associated with mitotane response and preliminarily explore potential agents for ACC.

Methods

In vitro mitotane sensitivity testing was performed in 17 PDCs and high-throughput screening against 40 compounds was conducted in 8 PDCs. Genetic features were evaluated in 9 samples using exomic and transcriptomic sequencing.

Results

PDCs exhibited variable sensitivity to mitotane treatment. The median cell viability inhibition rate was 48.4% (IQR: 39.3-59.3%) and -1.2% (IQR: -26.4-22.1%) in responders (n=8) and non-responders (n=9), respectively. Median IC50 and AUC were remarkably lower in responders (IC50: 53.4 µM vs 74.7 µM, P<0.0001; AUC: 158.0 vs 213.5, P<0.0001). Genomic analysis revealed CTNNB1 somatic alterations were only found in responders (3/5) while ZNRF3 alterations only in non-responders (3/4). Transcriptomic profiling found pathways associated with lipid metabolism were upregulated in responder tumors whilst CYP27A1 and ABCA1 expression were positively correlated to in vitro mitotane sensitivity. Furthermore, pharmacologic analysis identified that compounds including disulfiram, niclosamide and bortezomib exhibited efficacy against PDCs.

Conclusion

ACC PDCs could be useful for testing drug response, drug repurposing and guiding personalized therapies. Our results suggested response to mitotane might be associated with the dependency on lipid metabolism. CYP27A1 and ABCA1 expression could be predictive markers for mitotane response, and disulfiram, niclosamide and bortezomib could be potential therapeutics, both warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitotaneAdrenocortical CarcinomaAdrenal Cortex NeoplasmsAntineoplastic Agents, HormonalPharmacogenomic TestingHumansFemaleMaleMiddle AgedAdultAgedPharmacogenetics

Stichwörter der Autor:innen

adrenocortical carcinomagenetic analysishigh-throughput screeningmitotanepatient-derived cells

Substanzen

MitotaneAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Disea…
  • Department of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Zitieren

APA

Zhang, J., Wu, L., Su, T., Liu, H., Jiang, L., Jiang, Y., Wu, Z., Chen, L., Li, H., Zheng, J., Sun, Y., Peng, H., Han, R., Ning, G., Ye, L., & Wang, W. (2024). Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1365321

Vancouver

Zhang J, Wu L, Su T, Liu H, Jiang L, Jiang Y, et al. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1365321

BibTeX
@article{Zhang2024,
  author = {Zhang, Jie and Wu, Luming and Su, Tingwei and Liu, Haoyu and Jiang, Lei and Jiang, Yiran and Wu, Zhiyuan and Chen, Lu and Li, Haorong and Zheng, Jie and Sun, Yingkai and Peng, Hangya and Han, Rulai and Ning, Guang and Ye, Lei and Wang, Weiqing},
  title = {Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics},
  journal = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1365321}
}
Kostenlos starten →